Measuring breast, colorectal, and prostate cancer screening with medicare claims data.
Measuring breast, colorectal, and prostate cancer screening with medicare claims data.
复制标题
使用医疗保险索赔数据衡量乳腺癌、结直肠癌和前列腺癌筛查情况。
DOI：
10.1097/00005650-200208001-00005
复制
发表时间：
2002
期刊：
影响因子：
3
通讯作者：
Cooper,GregoryS
中科院分区：
文献类型：
--
作者：
Freeman,JeanL;Klabunde,CarrieN;Schussler,Nicola;Warren,JoanL;Virnig,BethA;Cooper,GregoryS
Background.Evaluating the use and effectiveness of cancer screening is an important component of cancer control programs. Medicare claims may be a useful source of data when screening older populations, but they are limited in terms of completeness and the ability to distinguish screening tests from those provided for diagnosis or surveillance.Research Design.A review of the major screening modalities for breast, colorectal, and prostate cancer, Medicare’s policies for covering these tests, and the procedure codes used to identify them in Medicare claims.Results.Although Medicare’s coverage has been extended to include screening mammography, colonoscopy, sigmoidoscopy, fecal occult blood tests, double-contrast barium enema, and prostate-specific antigen tests, providers have been slow to adopt the corresponding screening codes.Conclusion.Challenges persist in measuring screening use, and innovative approaches are required to distinguish screening tests from diagnostic and follow-up evaluations.
